Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney disease and type 2 diabetes (finerenone).